0.000USD0.000盤前交易 07/28, 09:30 (美東)
關鍵數據
17.330今開
17.750最高
9.76M成交量
虧損本益比TTM
6.62本益比動
0.480股利TTM
0.85%換手率
17.240昨收
17.280最低
125.44M成交額
虧損本益比靜
1.38市淨率
2.72%股息率 TTM
-0.79%ROA
17.53052週最高
1.05量比
-634.20M淨利潤
1.15B總股本
-0.2986每股盈餘TTM
0.89Beta
-1.96%ROE
8.40052週最低
2.73%振幅
39.18%毛利率
20.30B總市值
3.02回報/風險
1.84%風險率
操作建議
Viatris Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名30/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為17.59。中期看,股價處於上升通道。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Viatris Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Viatris Inc簡介
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
公司代碼VTRS
公司Viatris Inc
CEOSmith (Scott A)
網址https://www.viatris.com/en
公司股東
常見問題
Viatris Inc(VTRS)的當前股價是多少?
Viatris Inc(VTRS)的當前股價是 17.64。
Viatris Inc股票的52週最高點是多少?
Viatris Inc股票的52週最高點是17.53。
Viatris Inc股票的52週最低點是多少?
Viatris Inc股票的52週最低點是8.40。
現在Viatris Inc(VTRS)的股票是買入、持有還是賣出?
根據分析師評級,Viatris Inc(VTRS)的總體評級為買入,目標價格為17.59。
Viatris Inc(VTRS)股票的每股收益(EPS TTM)是多少
Viatris Inc(VTRS)股票的每股收益(EPS TTM)是-3.00。